Sichenzia Ross Ference LLP Represents Aegis Capital Corp. in $8 Million Underwritten Public Offering of BiondVax Pharmaceuticals Ltd.
Press Release – New York, NY – December 21, 2022 – Sichenzia Ross Ference LLP today announced that it represented Aegis Capital Corp. as sole book running manager in the $8 Million underwritten public offering of BiondVax Pharmaceuticals, a biotechnology company which focuses on developing, manufacturing, and commercializing innovative immunotherapeutic products. The offering consisted of 1,600,000 units and pre-funded units, with each unit consisting of one American Depositary Share (“ADS”) and two warrants, each to purchase one ADS, at a combined purchase price of $5.00 per unit (or $4.999 per pre-funded unit after reducing $0.001 attributable to the exercise price of the pre-funded warrants). The gross proceeds of the offering to the company were approximately $8 million.
The shares were issued pursuant to a Form F-1 registration statement (No. 333-267648) filed with the Securities and Exchange Commission (SEC) and declared effective by the SEC on December 15, 2022. The Sichenzia Ross Ference LLP team was led by partners Gregory Sichenzia, Darrin Ocasio, Barrett DiPaolo, and associates Matthew Siracusa and Mayank Pradhan.
- Sichenzia Ross Ference LLP Represents Verb Technology Company, Inc. in $7.2 Million Underwritten Public Offering of Common Stock - January 26, 2023
- Sichenzia Ross Ference LLP Represents Jupiter Wellness, Inc. in $4.1 Million Registered Direct Offering and Concurrent Private Placement of Warrants - January 24, 2023
- Sichenzia Ross Ference LLP Represents Network 1 Financial Securities, Inc. in $69 Million Public Offering of Horizon Space Acquisition I Corp. - January 9, 2023